Executive Summary
FDA Commissioner Marty Makary outlined 42 major regulatory reforms implemented in his first 10 months, fundamentally restructuring drug approval processes to compete with China's 4-week Phase 1 trials versus America's historical multi-year timelines. The agency eliminated dual pivotal trial requirements, reducing development costs by $100-300 million per drug, while launching unprecedented pilot programs delivering approvals in 55 days. Makary's team achieved 100% user fee target compliance in 2025 and approved record numbers of cell and gene therapies. The restructuring consolidated duplicative services (2,000 HR staff reduced to baseline levels) while hiring 1,050 new scientists for accelerated pathways. Most significantly, the FDA negotiated most-favored-nation pricing with pharmaceutical companies, potentially reducing GLP-1 costs from $1,300 to $149 for three months. Biosimilar approval timelines compressed from 5-8 years to 2.5 years with $100+ million cost reductions. The administration simultaneously moved toward over-the-counter transitions for non-abuse-potential drugs, bypassing PBM intermediaries. These structural changes address the core competitiveness gap where Chinese companies increased from 5% to 42% of licensing deals between 2022-2025, while China now publishes 50% more scientific papers than the US.
Key Insights
what Marty Makary said“We announced just last month that we are going to go from a baseline default requirement of two pivotal trials for a drug to one pivotal trial for a drug. It's just math. You can achieve the same statistical power if you design one good clinical trial properly”
This is a preview. Log in to see the full analysis including investment opportunities, risks, catalysts, and detailed insights.